Compounds for the treatment of metabolic disorders

Details Compounds for the treatment of metabolic disorders Compounds for the treatment of metabolic disorders

2011-03-29

2011-03-29

Chandrakumar, Nizal S (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C549S293000, C549S323000, C549S328000

Reexamination Certificate

active

07915429

ABSTRACT:
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed, wherein n is 1 or 2; m is 0, 1, 2, 3 or 4; q is 0 or 1; t is 0 or 1; R1is alkyl having from 1 to 3 carbon atoms; R2is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula (I) by a ring carbon. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of formula (I).

REFERENCES:
patent: 6011060 (2000-01-01), Laurent et al.
patent: 6858602 (2005-02-01), Sharma et al.
patent: 6916848 (2005-07-01), Sharma
patent: 6924314 (2005-08-01), Sharma et al.
patent: 6946491 (2005-09-01), Sharma et al.
patent: 7012071 (2006-03-01), Sharma et al.
patent: 7041659 (2006-05-01), Sharma
patent: 7045541 (2006-05-01), Sharma
patent: 7101910 (2006-09-01), Sharma
patent: 7329782 (2008-02-01), Sharma et al.
patent: 7361686 (2008-04-01), Hodge et al.
patent: 2002/0064847 (2002-05-01), Yamamoto et al.
patent: 2005/0090555 (2005-04-01), Sharma et al.
patent: 2006/0014784 (2006-01-01), Hodge et al.
patent: 2006/0035970 (2006-02-01), Hodge et al.
patent: 2006/0247309 (2006-11-01), Hodge et al.
patent: 2007/0105958 (2007-05-01), Sharma et al.
patent: 2007/0173544 (2007-07-01), Hodge et al.
patent: 2007/0249696 (2007-10-01), Sharma et al.
patent: 2007/0249719 (2007-10-01), Sharma et al.
patent: 2007/0265322 (2007-11-01), Sharma et al.
patent: 2007/0282003 (2007-12-01), Sharma et al.
patent: 2008/0015209 (2008-01-01), Sharma et al.
patent: 2008/0015254 (2008-01-01), Sharma et al.
patent: 2008/0021109 (2008-01-01), Sharma et al.
patent: 2008/0027229 (2008-01-01), Hodge et al.
patent: 19617864 (1997-10-01), None
patent: 00/23409 (2000-04-01), None
patent: 02/100341 (2002-12-01), None
patent: 2004/073611 (2004-09-01), None
patent: 2004/091486 (2004-10-01), None
Pelletier et al. Bioorganic & Medicinal Chemistry (2005), 13(21),5986-5995.
Au, et al. “Activation of Ftorafur [R,S-1-(Tetrahydro-2-furanyl)-5-fluorouracil] to 5-Fluorouracil and y-Butyrolactone1”, Cancer Research, vol. 40, pp. 2814-2819, 1980.
Younis, et al., “The prevention of type 2 diabetes mellitus: recent advances”, QJ Med., vol. 97, pp. 451-455, 2004.
Goff, et al., “Prevention of Cardiovascular Disease in Persons with type 2 diabetes Mellitus: Current Knowledge and Rational for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial”, AM J Cardiol., 99(12A): S4-S20, 2007. (Abstract).
Knowler, et al., “Perspectives in Diabetes: Preventing Non-Insulin-Dependent Diabetes”, Diabetes, vol. 44, pp. 483-488, 1995.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,515.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,520.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,560.
Pending (as of Sep. 25, 2008) claims from U.S. Appl. No. 12/294,530.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,854.
Pending (as of Jul. 28, 2008) claims from U.S. Appl. No. 12/162,397.
Pending (as of May 7, 2008) claims from U.S. Appl. No. 12/092,932.
Pending (as of Aug. 18, 2008) claims from U.S. Appl. No. 12/160,808.
Pending (as of Aug. 13, 2008) claims from U.S. Appl. No. 12/279,247.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,858.
Pelletier, et al., “Preparation of highly substituted γ-lactam follicle stimulating hormone receptor agonists”, Bioorganic & Medical Chemistry, 13:5986-5995, 2005.

Affiliated with

Also associated with

Rating

Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2738386